Portfoliotracker

OnKure Therapeutics, Inc.

OKUR · NASDAQGM · Healthcare Biotechnology 22/100 E

2,750 $
▲ +0,120 (+4,56 %)
Pre-market delayed by 15 min
Price as of 16. 11. 22:00, fetched 17. 11. 13:55
Next earnings–
Ex-dividend–
Analysts–
50 / 200 day average– / –

Price

Portfoliotracker score22 / 100 Market cap137 mil. $ P/E– Forward P/E-1,7 P/S– P/B0,9 EV/EBITDA– Dividend yield– FCF yield-34,91 % EPS-2,37 $ Net margin0,0 % Return on equity-55,2 % Beta0,73 Debt / equity0,01
52-week range 2,01 to 5,38
3-month average volume0,3 M

Finance

Where the revenue goes

Loading the income statement flow…

Fundamentals

Loading key figures…

Insiders, analysts and people

All trades and changes

Loading insiders, analysts and opinions…

Co se právě děje

AI souhrn
Objednat AI souhrn, co se u firmy právě děje Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

About the company

OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company was founded in 2011 and is headquartered in Boulder, Colorado.

Employees
45
Country
United States
Fiscal year end
31. 12.
Data since
8. 4. 2021

Explore further

Similar companies LXEOTECXCLYMARTVNGNE

Intraday chart

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account